Holen Sie sich die Stockscreener-App
49.05
1.22%
0.59
Handel nachbörslich:
48.70
-0.35
-0.71%
Schlusskurs vom Vortag:
$48.46
Offen:
$49.36
24-Stunden-Volumen:
546.20K
Relative Volume:
1.39
Marktkapitalisierung:
$1.03B
Einnahmen:
$1.77M
Nettoeinkommen (Verlust:
$-123.74M
KGV:
-5.349
EPS:
-9.17
Netto-Cashflow:
$-95.21M
1W Leistung:
+0.93%
1M Leistung:
-2.95%
6M Leistung:
-43.40%
1J Leistung:
-6.11%
1-Tages-Spanne:
$47.94
$49.97
1-Wochen-Bereich:
$44.25
$49.97
52-Wochen-Spanne:
$26.70
$91.83
Praxis Precision Medicines Inc Stock (PRAX) Company Profile
Firmenname
Praxis Precision Medicines Inc
Sektor
Branche
Telefon
617-300-8460
Adresse
99 HIGH STREET, 30TH FLOOR, BOSTON
Vergleichen Sie PRAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PRAX
Praxis Precision Medicines Inc
|
49.05 | 1.02B | 1.77M | -123.74M | -95.21M | -9.17 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Praxis Precision Medicines Inc Stock (PRAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-02 | Fortgesetzt | Oppenheimer | Outperform |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-03-03 | Bestätigt | H.C. Wainwright | Buy |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-08-05 | Eingeleitet | Oppenheimer | Outperform |
| 2024-06-24 | Eingeleitet | Needham | Buy |
| 2024-06-18 | Eingeleitet | Guggenheim | Buy |
| 2024-05-01 | Eingeleitet | Robert W. Baird | Outperform |
| 2023-09-19 | Eingeleitet | Truist | Buy |
| 2022-06-06 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-12-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-26 | Eingeleitet | BofA Securities | Buy |
| 2021-04-26 | Eingeleitet | William Blair | Outperform |
| 2020-11-11 | Eingeleitet | Wedbush | Outperform |
| 2020-11-10 | Eingeleitet | Cowen | Outperform |
| 2020-11-10 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-10 | Eingeleitet | Piper Sandler | Overweight |
Alle ansehen
Praxis Precision Medicines Inc Aktie (PRAX) Neueste Nachrichten
PRAX Investors Have Opportunity to Join Praxis Precision Medicines, Inc. Fraud Investigation with the Schall Law Firm - Business Wire
Levi & Korsinsky Investigating Whether Praxis Precision Medicines, Inc. (PRAX) Misled InvestorsSecurities Law Violations Possible - ACCESS Newswire
What are the future prospects of Praxis Precision Medicines Inc.Volume Surge With Low Float - thegnnews.com
Investigation Alert: Levi & Korsinsky Investigates Securities Fraud Claims Against Praxis Precision Medicines, Inc. (PRAX) - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Praxis Precision Medicines, Inc.PRAX - PR Newswire
Piper Sandler reiterates Overweight rating on Praxis Precision Medicines stock - Investing.com Nigeria
ATTENTION PRAX Shareholders: Lost Money on Praxis Precision Medicines, Inc.? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Praxis Precision Medicines Q2 results disappoint, stock falls 5.55% - AInvest
Is Praxis Precision Medicines Inc. stock reversal real or fakeSecure Trading Strategy Based on Technical Analysis - Newser
Is Praxis Precision Medicines Inc. meeting your algorithmic filter criteriaReal Market Tracker with Price Action Tools - Newser
Will Praxis Precision Medicines Inc. bounce back from current supportFree Capital Efficiency Optimized Stock Alerts - Newser
Reversal indicators forming on Praxis Precision Medicines Inc. stockFree Weekly Potential Breakout Stock List - Newser
What is HC Wainwright’s Forecast for PRAX Q3 Earnings? - Defense World
Praxis Precision Medicines’ (PRAX) “Buy” Rating Reiterated at HC Wainwright - Defense World
Praxis Precision Medicines’ Positive Earnings Call Highlights Vormatrigine Success - MSN
Praxis Precision Medicines: Marcio Firm's Insights - AInvest
What is Wedbush’s Forecast for PRAX Q3 Earnings? - Defense World
FY2029 Earnings Forecast for PRAX Issued By HC Wainwright - Defense World
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Praxis Precision Medicines Grants 3,875 Restricted Stock Units to Strategic New Hires - Stock Titan
Praxis Precision Medicines, Inc. (NASDAQ:PRAX) Q2 2025 Earnings Call Transcript - Insider Monkey
Praxis Precision Medicines Advances Epilepsy Treatment with Promising Study Results and Strong Financial Positioning - AInvest
Praxis Precision Medicines: A Dual-Platform Innovator Capturing the Future of Precision Neurology - AInvest
Praxis Precision Medicines to Participate in Upcoming Fireside C - GuruFocus
Praxis Precision Medicines to Participate in Upcoming Fireside Chat - GlobeNewswire
Praxis Precision Medicines, Inc. Investors: Company Investigated by the Portnoy Law Firm - GlobeNewswire
Praxis Precision Medicines stock holds Buy rating at Truist on seizure reduction data - Investing.com India
A Quick Look at Today's Ratings for Praxis Precision Medicines(PRAX.US), With a Forecast Between $33 to $155 - 富途牛牛
Praxis Precision Medicines First Half 2025 Earnings: US$6.60 loss per share (vs US$4.58 loss in 1H 2024) - Yahoo Finance
Praxis’ vormatrigine eliminates seizures in 22% of patients in Phase II trial - Yahoo Finance
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... - Yahoo Finance
Praxis Precision Medicines Reports Positive Phase 2 Study Results, Revenue Growth, and Strong Liquidity Position - AInvest
Praxis Precision Medicines Inc (PRAX) Q2 2025 Earnings Call Highlights: Vormatrigine Shows ... By GuruFocus - Investing.com Canada
Praxis Precision Medicines Reports Promising Study Results - TipRanks
Decoding Praxis Precision Medicines Inc (PRAX): A Strategic SWOT Insight - GuruFocus
Praxis Precision Medicines to Participate in Virtual Fireside Chat Hosted by Truist Securities - AInvest
Praxis Precision Medicines to Participate in Upcoming Fireside Chat | PRAX Stock News - GuruFocus
Praxis Precision Medicines Shares Surge on Promising Epilepsy Drug Data - MSN
Guggenheim raises Praxis Precision Medicines stock price target on positive seizure drug data - Investing.com Australia
Praxis Precision Medicines stock holds Buy rating at TD Cowen on promising seizure data - Investing.com Canada
Praxis: Positive 8-Week Radiant Study Data Leads To Other Expected Catalysts - Seeking Alpha
Praxis Precision Medicines stock price target raised by Wedbush to $33 - Investing.com Canada
Praxis’ epilepsy drug cut seizure frequency in mid-stage trial - Endpoints News
What's Going On With Praxis Precision Medicines Stock Monday?Praxis Precision Medicine (NASDAQ:PRAX) - Benzinga
Promising Potential of Praxis Precision Medicines: Buy Rating Affirmed by Douglas Tsao - TipRanks
Praxis Precision Medicines, Inc. 2025 Q2ResultsEarnings Call Presentation (NASDAQ:PRAX) - Seeking Alpha
A brain biotech slumps even with ‘best case’ seizure data - BioPharma Dive
Quitter jitters? Dropouts mar Praxis FOS vormatrigine phase II - BioWorld MedTech
Transcript : Praxis Precision Medicines, Inc., Q2 2025 Earnings Call, Aug 04, 2025 - MarketScreener
Praxis Precision Medicines Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Praxis (PRAX) Q2 Loss Widens 90% - The Motley Fool
Finanzdaten der Praxis Precision Medicines Inc-Aktie (PRAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):